Gain Therapeutics grants officer 130K stock options

Continued service through each vesting date is required for the options to vest.

Available on EDGAR 10/30/2026 - 05:11 PM EDT Accepted by SEC EDGAR 10/30/2026 - 05:10 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Gain Therapeutics, Inc. granted its Principal Accounting Officer and Principal Financial Officer, Jeanette Weidner, stock options covering 130,000 common shares on October 29, 2026. The options have a $1.19 per-share exercise price and expire October 29, 2036. They vest 25% on October 29, 2027, with the remainder vesting in 36 equal monthly installments, subject to Weidner’s continuous service through each vesting date. The reported post-award position is 130,000 options.

Insider Trade Summary

Grant/Award: 130,000 shares

Grant/Award 1 txn

Insider Weidner Jeanette

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	130,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 130,000 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying the Option shall vest as to 25% on October 29, 2027, and the remainder shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Key Figures

Stock options awarded: 130,000 options Exercise price: $1.19 per share First vesting percentage: 25% +2 more

5 metrics

Stock options awarded 130,000 options Direct award on October 29, 2026

Exercise price $1.19 per share Awarded options

First vesting percentage 25% Vests on October 29, 2027

Remaining vesting installments 36 equal monthly installments Subject to continuous service through each vesting date

Expiration date October 29, 2036 Stock options

Key Terms

Stock Option (right to buy), vest, continuous service

3 terms

Stock Option (right to buy) financial

"Stock Option (right to buy)"

vest technical

"shall vest as to 25%"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

continuous service technical

"subject to the Reporting Person’s continuous service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did GANX officer Jeanette Weidner receive, and what is the exercise price?

Jeanette Weidner received stock options covering 130,000 common shares at a $1.19 per-share exercise price on October 29, 2026.

When do Jeanette Weidner’s GANX stock options expire?

The options expire on October 29, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weidner Jeanette

(Last) (First) (Middle)

C/O GAIN THERAPEUTICS, INC.

4800 MONTGOMERY LANE, SUITE 220

(Street)

BETHESDA MARYLAND 20814

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Gain Therapeutics, Inc. [ GANX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.19	10/29/2026		A		130,000		(1)	10/29/2036	Common Stock	130,000	$0.00	130,000	D

Explanation of Responses:

1. The shares underlying the Option shall vest as to 25% on October 29, 2027, and the remainder shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

Principal Accounting Officer and Principal Financial Officer

	/s/ Jeanette Weidner	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)